论文部分内容阅读
目的探讨慢性乙型肝炎应用拉米夫定停药后复发临床治疗效果。方法 2007年1月至2010年1月诊治的符合入选标准慢性乙型肝炎应用拉米夫定停药后复发病例246例,再次抗病毒治疗,依据治疗药物不同分为阿德福韦酯组126例,拉米夫定组120例,观察两组与治疗前(0周)和治疗后8周、16周进行HBVDNA、ALT检测并进行比较。结果两组0周检测内容比较P>0.05差异无统计学意义。两组治疗后8周、16周检测内容比较P<0.05差异有统计学意义。两组疗后8周、16周检测内容与0周比较P<0.01有显著差异性。结论多数拉米夫定在治疗慢性乙型肝炎应用拉米夫定停药后复发中均有疗效,阿德福韦酯与拉米夫定不具有交叉耐药性,可以用于拉米夫定耐药或复发后的继续抗病毒治疗,效果更为突出。
Objective To investigate the clinical effect of relapse after lamivudine withdrawal in patients with chronic hepatitis B. Methods From January 2007 to January 2010, the patients were enrolled in this study. A total of 246 recurrent cases of chronic hepatitis B after lamivudine withdrawal were enrolled. After antiviral treatment again, they were divided into adefovir dipivoxil group 126 Cases, lamivudine group of 120 cases, observed two groups and before treatment (0 weeks) and 8 weeks after treatment, 16 weeks HBVDNA, ALT detection and comparison. Results There was no significant difference between the two groups in 0 week test content P> 0.05. The two groups after 8 weeks, 16 weeks test content comparison P <0.05 difference was statistically significant. There was a significant difference between the two groups in 8 weeks and 16 weeks after treatment as compared with 0 week (P <0.01). Conclusions Most lamivudine are effective in the treatment of chronic hepatitis B relapse after lamivudine withdrawal. Adefovir dipivoxil has no cross-resistance with lamivudine and can be used in lamivudine Resistance or relapse after the continuation of antiviral therapy, the effect is more prominent.